Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on October 23, 2026

IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
Arkansas Counties Open Roads to UTVs: What Riders Need Under Act 922
ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment
BranchOut Food Inc. Announces $5.0 Million Underwritten Public Offering
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
Edible Garden Announces Commercial Supply Agreement and Strategic Partnership with Caney Fork Farms
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
Super Vision Technology: World’s first i-NYS implant for congenital nystagmus in a Chinese boy
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
KFSH Marks Four Decades of Cardiac Innovation, from One Cath Lab to an Integrated Heart Center
Balchem Corporation Reports Third Quarter 2026 Financial Results
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
GigaCloud Technology Inc Ranks Among Top 15 on Fortune’s Fastest Growing Companies™ 2026 and TIME’s America’s Growth Leaders 2027 Lists
HIMS INVESTOR NOTICE: RGRD Law Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Alternative Medicine Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.